TNDM · Tandem Diabetes Care Inc.
AI read · Good for TNDM
The AI's read
William Blair initiated coverage on TNDM with an Outperform and points to a discounted 1.8x 2026 EV/sales multiple. Analyst endorsement plus a valuation gap can trigger a re-rate if execution holds. Market response is muted: TNDM is up 1.7% and RSI is 36.58, so the news hasn't fully re-priced the name. That leaves room for upside on better-than-expected execution or uptake. Macro is shaky and Medicare competitive bidding in 2028 is a clear pricing risk. We lean bullish on the setup but would keep position size conservative given policy and market risks.